Penn Medicine Study: Olaparib Shows Success in Tumor Response Rate for Patients with BRCA-Related Cancers
This post was written by our friends at uphs.upenn.edu
Olaparib, an experimental twice-daily oral cancer drug, produces an overall tumor response rate of 26 percent in several advanced cancers associated with BRCA1 and BRCA2 mutations, according to new research co-led by the Abramson Cancer Center of the University of Pennsylvania. The positive response provides new hope for patients with ovarian, breast, pancreatic and prostate cancers whose conditions have not responded to standard therapies. Results of the phase II study are available online in the current issue of the Journal of Clinical Oncology.
Last Updated November 22, 2018